210 related articles for article (PubMed ID: 18430791)
1. Confirmed beta16 Arg/Arg polymorphism in a patient with uncontrolled asthma.
Metzger NL; Kockler DR; Gravatt LA
Ann Pharmacother; 2008 Jun; 42(6):874-81. PubMed ID: 18430791
[TBL] [Abstract][Full Text] [Related]
2. Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response.
Peters S
Curr Med Res Opin; 2007 Sep; 23 Suppl 3():S29-36. PubMed ID: 17925066
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of tiotropium for patients with asthma.
Bollmeier SG; Lee SY
Ann Pharmacother; 2013 May; 47(5):704-13. PubMed ID: 23613100
[TBL] [Abstract][Full Text] [Related]
4. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD.
Umeda N; Yoshikawa T; Kanazawa H; Hirata K; Fujimoto S
Respirology; 2008 May; 13(3):346-52. PubMed ID: 18399855
[TBL] [Abstract][Full Text] [Related]
5. Tachyphylaxis to beta2-agonists in Spanish asthmatic patients could be modulated by beta2-adrenoceptor gene polymorphisms.
Tellería JJ; Blanco-Quirós A; Muntión S; Antonio Garrote J; Arranz E; Armentia A; Díez I; Castro J
Respir Med; 2006 Jun; 100(6):1072-8. PubMed ID: 16263254
[TBL] [Abstract][Full Text] [Related]
6. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Israel E; Drazen JM; Liggett SB; Boushey HA; Cherniack RM; Chinchilli VM; Cooper DM; Fahy JV; Fish JE; Ford JG; Kraft M; Kunselman S; Lazarus SC; Lemanske RF; Martin RJ; McLean DE; Peters SP; Silverman EK; Sorkness CA; Szefler SJ; Weiss ST; Yandava CN
Am J Respir Crit Care Med; 2000 Jul; 162(1):75-80. PubMed ID: 10903223
[TBL] [Abstract][Full Text] [Related]
7. What is new with the beta2-agonists: issues in the management of asthma.
Kelly HW
Ann Pharmacother; 2005 May; 39(5):931-8. PubMed ID: 15811904
[TBL] [Abstract][Full Text] [Related]
8. Is there a problem with inhaled long-acting beta-adrenergic agonists?
Nelson HS
J Allergy Clin Immunol; 2006 Jan; 117(1):3-16; quiz 17. PubMed ID: 16387577
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
Baker WL; Baker EL; Coleman CI
Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
[TBL] [Abstract][Full Text] [Related]
10. Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.
Giubergia V; Gravina L; Castaños C; Chertkoff L
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):156-60. PubMed ID: 23548523
[TBL] [Abstract][Full Text] [Related]
11. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
Chen AM; Bollmeier SG; Finnegan PM
Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
[TBL] [Abstract][Full Text] [Related]
12. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
[TBL] [Abstract][Full Text] [Related]
13. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response.
Park HW; Yang MS; Park CS; Kim TB; Moon HB; Min KU; Kim YY; Cho SH
Allergy; 2009 May; 64(5):778-83. PubMed ID: 19183167
[TBL] [Abstract][Full Text] [Related]
14. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
Drescher GS; Carnathan BJ; Imus S; Colice GL
Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
[TBL] [Abstract][Full Text] [Related]
15. A safety review of long-acting beta2-agonists in patients with asthma.
Rider NL; Craig TJ
J Am Osteopath Assoc; 2006 Sep; 106(9):562-7. PubMed ID: 17079526
[TBL] [Abstract][Full Text] [Related]
16. Clinical consequences of ADRbeta2 polymorphisms.
Hawkins GA; Weiss ST; Bleecker ER
Pharmacogenomics; 2008 Mar; 9(3):349-58. PubMed ID: 18303970
[TBL] [Abstract][Full Text] [Related]
17. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of risk factors and health outcomes among persons with asthma.
Smith K; Warholak T; Armstrong E; Leib M; Rehfeld R; Malone D
J Asthma; 2009 Apr; 46(3):234-7. PubMed ID: 19373629
[TBL] [Abstract][Full Text] [Related]
19. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline.
Rebordosa C; Kogevinas M; Guerra S; Castro-Giner F; Jarvis D; Cazzoletti L; Pin I; Siroux V; Wjst M; Antò JM; de Marco R; Estivill X; Corsico AG; Nielsen R; Janson C
Eur Respir J; 2011 Nov; 38(5):1029-35. PubMed ID: 21436355
[TBL] [Abstract][Full Text] [Related]
20. Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children.
Giubergia V; Gravina LP; Castaños C; Chertkoff L; Grenoville M
Pediatr Pulmonol; 2008 May; 43(5):421-5. PubMed ID: 18383333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
